

## CURRICULUM VITAE

### **Richard D. Knapp, D.O.**

Florida Clinical Research Center, LLC  
2300 Maitland Center Parkway, Suite 230  
Maitland, FL 32751  
Tel. (407) 644-1165  
rknapp@flcrc.com

#### **CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, Site Liaison  
Tel. (866) 669-0234  
Fax (208) 575-3169  
Email: clinicaltrials@btheodore.com

#### **AFFILIATIONS:**

Lakeside Behavioral Healthcare  
434 W. Kennedy Blvd.  
Orlando, FL 32810

Florida Clinical Research Center, LLC  
3914 State Road 64 East  
Bradenton, FL 34208

#### **EDUCATION:**

1967 Bachelor of Science in Biology  
Farleigh Dickinson University, Madison, New Jersey

1971 Doctor of Osteopathic Medicine  
Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania

#### **RESIDENCY:**

1972-1975 Residency in Psychiatry  
Philadelphia Psychiatric Center (now Belmont Behavioral Health), Philadelphia, Pennsylvania

#### **CERTIFICATION:**

American Board of Psychiatry and Neurology, Certified in Addictions Psychiatry, March, 1993

American Board of Psychiatry and Neurology, Certified in Psychiatry, November, 1985

**LICENSURE:**

DO License: Number available on request

Drug Enforcement Agency License: Number available on request

**PROFESSIONAL EXPERIENCE:**

*Principal Investigator*, February 2001- Present  
Florida Clinical Research Center, LLC

*General, Geriatric and Addictions Psychiatry*, 1986-2001  
Private Practice, Hollywood, Florida

*Assistant Associate Clinical Professor*. 1983-1994  
Nova Southeastern University, College of Osteopathic Medicine, Miami, Florida

*General, Geriatric and Addictions Psychiatry*, 1982-1986  
Private Practice, North Miami, Florida

*Clinical Director, Adolescent Substance Abuse Program*, 1982-1986  
Humana Hospital of South Broward, Hallandale, Florida

*General Medicine*, 1979-1982  
Private Practice, Miami, Florida

**INVESTIGATOR EXPERIENCE:**

ADHD (Attention-Deficit Hyperactivity Disorder) • Alzheimer's Disease • Anxiety Disorders  
Bipolar Disorder • Cognition • Diabetic Peripheral Neuropathy (DPN)  
Depression • Fibromyalgia • Migraine • Osteoarthritis • Schizophrenia  
Shingles Pain / Herpes Zoster • Sleep Disorders • Substance Abuse and Other Addictions

**ADDITIONAL TREATMENT EXPERIENCE:**

Obesity • Pediatric Disorders • Sexual Dysfunction • Smoking Cessation

**CLINICAL TRIAL EXPERIENCE:**

*Alzheimer's Disease*

A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer's Disease using Alzheimer's Disease Medication

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase III, Multi-center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate the Safety and Tolerability of XXX For Up To 26-Weeks in Patients with Mild to Moderate Alzheimer's Disease

***ADHD***

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXX in Adults with Attention Deficit Hyperactivity Disorder

A Phase III, Randomized, Double-Blind, Multi-center, Parallel-Group, Placebo-Controlled, Dose Optimization Study Designed to Evaluate the Safety and Efficacy of XXX System vs. XXX in Pediatric Patients Aged 6-12 with ADHD

A Open Label Study of XXX in Children and Adolescents Aged 16-17 with Attention Deficit Hyperactivity Disorder

A Phase III, Open Label Study of XXX in Children and Adolescents with ADHD

A 12-Month, Open Label Study of XXX in Adults with Attention Deficit Hyperactivity Disorder

***Anxiety***

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of Two Doses of XXX in Acute Treatment of Adults with Generalized Anxiety Disorder

A Randomized, Double-Blind, XXX- and Placebo-Controlled Study of the Efficacy and Safety of XXX in Outpatients with Generalized Anxiety Disorder

A Double-Blind, Placebo-Controlled Study of XXX ER in Children and Adolescents with Generalized Anxiety Disorder

A Flexible Dose Comparison of the Safety and Efficacy of XXX and Placebo in the Treatment of Generalized Anxiety Disorder

A Four-Week, Double-Blind, Placebo- and Active-Controlled, Dose-Ranging Study of XXX, Three Doses and XXX in Outpatients with Generalized Anxiety Disorder (GAD)

An Open Label Extension Study of the Safety and Efficacy of XXX in Patients with Generalized Anxiety Disorder

**CLINICAL TRIAL EXPERIENCE (continued):**

***Bipolar Disorder***

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXX in Patients with Acute Mania Associated with Bipolar I Disorder

A 24-Week, Flexible-Dose, Open-Label Extension Study of XXX for the Treatment of Bipolar I Depression

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Flexible Doses of XXX in the Maintenance Treatment of Patients with Bipolar Disorder

A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy Trial of the Use of XXX in the Treatment of Patients with Bipolar Depression

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Flexible Doses of XXX in the Maintenance Treatment of Patients with Bipolar Disorder

An Efficacy and Safety of Flexible Dosage Ranges of XXX vs. Placebo in the Treatment of Manic Episodes Associated with Bipolar I Disorder

A Three-Week, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Extended Release XXX in XXX-Failure Patients with Bipolar Disorder

A Multi-center, Randomized, Double-Blind Study of XXX vs. Placebo in the Treatment of Acutely Manic Patients with Bipolar Disorder

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of XXX in the Maintenance Treatment of Patients with Bipolar Disorder

An XXX vs. XXX in the Treatment of Bipolar I Disorder, Manic or Mixed

A Phase III, Three-Week, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Extended Release XXX in the Treatment of Bipolar I Disorder

A 21-Day Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of XXX ER in the Treatment of the Manic Phase of Bipolar Disorder

A Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of XXX in the Treatment of Bipolar I Disorder, Most Recent Episode Depressed

A Six-Month, Open Label, Multi-center Study of Extended-Release XXX in Patients with Bipolar Disorder

**CLINICAL TRIAL EXPERIENCE (continued):**

A Nine-Week, Open Label, Multi-center Trial of Flexible Dose Ranges of XXX in the Treatment of Manic Episodes Associated with Bipolar I Disorder

A Multi-center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of XXX as Add-on Therapy with XXX or XXX in the Treatment of Acute Mania

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Flexible Doses of XXX in the Treatment of Hospitalized Patients with Acute Mania

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Two Fixed Doses of XXX in the Treatment of Hospitalized Patients with Acute Mania

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of XXX Mono-Therapy in the Treatment of Acutely Manic Patients with Bipolar I Disorder

***Depression***

A Phase III, Randomized, double-blind, parallel-group, placebo-controlled, fixed dose study on the efficacy of XXX on cognitive dysfunction in adult patients with Major Depressive Disorder (MDD)

A Phase II, Multicenter, Open-label Study to Assess the Safety and Tolerability of XXX as Adjunctive Therapy in Adult Patients with Major Depressive Disorder

A 52-week, multi-center, open-label study of the safety and tolerability of XXX tablets in patients with Major Depressive Disorder (MDD)

A Double-Blind, Randomized, Multi-Center, Placebo-Controlled, Relapse Prevention Study with XXX in Out-Patient Adults with Major Depressive Disorder

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, XXX-Referenced, Fixed Dose Study Comparing the Efficacy and Safety of XXX in Acute Treatment of Major Depressive Disorder in Elderly Patients

A Multi-center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Functional Outcome in Outpatients with Major Depressive Disorder Treated with XXX

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of XXX in the Treatment of Patients with Bipolar I Disorder with a Major Depressive Episode

A Phase IIb, Six-Week, Double-Blind, Placebo- and XXX-Controlled Multi-center Study to Evaluate the Safety and Efficacy of Oral XXX in Outpatients with Major Depressive Disorder

A Six-Week, Double-Blind Extension of a Phase IIb, Double-Blind, Placebo- and XXX-Controlled Multi-center Study to Evaluate the Safety and Efficacy of Oral XXX in Outpatients with Major Depressive Disorder

**CLINICAL TRIAL EXPERIENCE (continued):**

A Flexible Dose Comparison of the Safety and Efficacy of XXX and Placebo in the Treatment of Major Depressive Disorder

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXX in Patients with Major Depressive Disorder with Psychotic Features

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXX in Patients with Major Depressive Disorder with Psychotic Features Who Are Not Receiving Antidepressants or Antipsychotics

A Double-Blind Comparison of the Safety and Efficacy of XXX and XXX in the Treatment of XXX Non-responders

A Two-Week, Double-Blind, Placebo-Controlled Study of XXX in the Treatment of Severe Major Depressive Disorder

A Controlled Trial of XXX vs. XXX in the Treatment of Schizophrenic and Schizoaffective Subjects with Comorbid Depression

A Double-Blind, Placebo- and XXX-Controlled Multi-center, Dose-Ranging Study Evaluating the Efficacy and Safety of XXX in Outpatients with Severe Major Depressive Disorder

A Maintenance of Antidepressant Effect of XXX in Geriatric Outpatients

An Eight-Week, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of Two Doses of XXX and XXX in Subjects with Major Depressive Disorder

A Phase III Open Label Study of the Safety and Efficacy of XXX in Patients with Major Depressive Disorder with Psychotic Features Who Have Previously Demonstrated a Rapid Response to XXX or Placebo in Study XXX or XXX

***Pain***

A Phase IIa, Multi-center, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of XXX for Migraine Prophylaxis in Patients with Episodic Migraine

A Phase IIb, Randomized, Double-Blind, Active and Placebo Controlled, Parallel-Group Study to Assess the Efficacy and Safety of XXX Compared to Placebo and XXX in Adult Patients with Acute Migraine With or Without Aura

A Multicenter, Randomized, Double-Blind (with in-house blinding), Active-Controlled, Parallel-Group Clinical Trial to Evaluate the Long Term Safety, and Tolerability of Oral XXX in Adults with Acute Migraine With or Without Aura.

**CLINICAL TRIAL EXPERIENCE (continued):**

A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of XXX for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine

A Phase II, Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of XXX in the Prophylaxis of Migraine Headache

A Phase II, Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging, Open Label Extension Study of the Efficacy and Tolerability of XXX in the Prophylaxis of Migraine Headache

A Randomized Withdrawal, Multi-center, Open-Label, Multiple-Dose, Long-Term Safety Study Randomized, Open-Label, Parallel-Group, Multiple-Dose, Long-Term Safety Study in Subjects with Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

A Phase III Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multi-center Study of the Analgesic Efficacy, Safety, and Tolerability of XXX in Patients with Osteoarthritis of the Knee or Hip

A Phase II, Multi-center, Randomized, Double-Blind, Parallel-Group, Comparative Study of XXX vs. XXX in Patients with Herpes Zoster

***Schizophrenia***

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of XXX versus Placebo in Patients with DSM-IV-TR Schizophrenia

A Long-Term, Open-Label, Multicenter Study of XXX Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

A 12-week, Randomized, Multicenter, Open-label, XXX Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients currently receiving XXX , XXX or XXX

A Phase III, Multicenter, Double-Blind Comparison of XXX and XXX in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with XXX

A Phase III, Open-Label, Multicenter, Rollover, Long-term Study of XXX Intramuscular Depot in Patients with Schizophrenia

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase IIa, Multi-center, Double-Blind, Randomized, Parallel Group, 4-Week Inpatient Treatment Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Two Fixed Doses of XXX Compared to Placebo, Using XXX as an Active Control, in the Treatment of Acute Exacerbation of Schizophrenia

A Phase II, 6-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX Once Daily and XXX Once Daily for Treatment of Hospitalized Adult Patients with Acute Schizophrenia and Extension Study

A Phase II, Multi-center, Open-label Study to Assess the Safety and Tolerability of XXX Flexible-dosed as Monotherapy in Adult Patients with Schizophrenia

A 38-Week, Multi-center, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of XXX as Maintenance Treatment

A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of XXX in Patients with Schizophrenia

A Phase III Randomized, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Two Doses of XXX in Acutely Psychotic Subjects with Schizophrenia

A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of XXX in Acutely Psychotic Patients with Schizophrenia

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXX in the Acute Exacerbation of Schizophrenia

A Randomized, Double-Blind, Placebo- and XXX-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of XXX Given Bid for 28 Days in Schizophrenic Patients in Acute Exacerbation Followed by a Long-Term Treatment Phase

A Double-Blind, Randomized, Fixed-Dose, Placebo-Controlled, Parallel-Group, Six-Week Efficacy, Safety, and Tolerability Study of Two Dose Levels of XXX in Patients with Schizophrenia by DSM-IV Criteria Who Are Experiencing an Acute Exacerbation of Symptoms

A Multi-center, Double-Blind, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation XXX and Placebo in the Treatment of Patients with Schizophrenia

A Controlled Trial of XXX vs. XXX in the Treatment of Schizophrenic and Schizoaffective Subjects with Prominent Negative Symptoms

**CLINICAL TRIAL EXPERIENCE (continued):**

A Multi-center, Double-Blind, Randomized Comparison of the Safety and Efficacy of XXX and XXX in the Treatment of Patients with Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, XXX-Referenced, Dose Finding Study of XXX in the Treatment of Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of Three Fixed Doses of XXX in Subjects with Schizophrenia

A Multi-center, Double-Blind, Randomized Comparison of the Efficacy and Safety of XXX and XXX in the Patients with Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of XXX ER Plus an Atypical Antipsychotic vs. an Atypical Antipsychotic Alone in the Acute Treatment of Schizophrenia

A Multi-center, Randomized, Double-Blind Study on the Effects of XXX on Overweight Patients Treated with XXX for Schizophrenia or Schizoaffective Disorder

A Multi-center, Open Label, Acceptability Study of XXX Oral Solution in the Treatment of Outpatients with Chronic Schizophrenia

A Multi-center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel-Group Evaluation of the Efficacy and Safety of A Fixed-Dose of XXX vs. Placebo vs. XXX in Subjects with Schizophrenia

An XXX vs. XXX in the Treatment of Acutely Ill Patients with Schizophrenia

An Assessment of the Efficacy and Safety of Two Sublingual Doses of XXX in Subjects with Schizophrenia (in an Acutely Exacerbated State) Compared to Placebo in a Multi-center Randomized, Double-Blind, Fixed-Dose, Six-Week Trial with a XXX Positive Control Group

A Randomized, Double Blind, Placebo-Controlled, XXX-Referenced, Dose Finding Study of XXX in Treatment of Schizophrenia

A Cost-Effectiveness and Functional Outcomes of XXX in the Treatment of Schizophrenia in Usual Clinical Practice: A Randomized Clinical Study

A Prospective, Multi-center, Open Label Study of XXX in the Management of Patients with Schizophrenia and Schizoaffective Disorder in General Psychiatric Practices

***Sleep Disorders***

A Phase II Randomized, Double-Blind, Placebo-and Active-Comparator-Controlled Study of the Safety and Efficacy of XXX in Outpatients with Insomnia

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase III, Randomized, Double-Blind, Placebo-Controlled Outpatient Safety and Efficacy Study of XXX in Elderly Subjects with Chronic Insomnia

A Phase III, Randomized, Double-Blind, Placebo-Controlled Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXX in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties

A Phase III, Open Label, Fixed Dose Study to Determine the Safety of Long-Term Administration of XXX in Subjects with Chronic Insomnia

A Phase III, Randomized, Double-Blind, Placebo-Controlled Outpatient Safety and Efficacy Study of XXX in Adults with Chronic Insomnia

A Phase III, Open Label, Outpatient Extension Study to Assess the Long-Term Safety of A Modified Release Formulation of XXX in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties

***Other Indications***

A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study with Follow-up Evaluating the Safety and Efficacy of XXX for Smoking Cessation in Healthy Adolescent Smokers

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXX vs. Placebo for the Treatment of Relapse Prevention in Alcohol Dependence

An Open Label, Follow-on Study of the Long-Term Safety of XXX Administered Orally to Patients with Psychotic Disorders or Psychotic Behaviors of Dementia